This study is not yet accepting patients

Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring

a study on Interstitial Lung Disease Idiopathic Pulmonary Fibrosis Fibrosis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Erica Farrand, MD (ucsf)
Headshot of Erica Farrand
Erica Farrand

Description

Summary

The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.

Details

Participants in this 12-month study will use home-based monitoring tools provided by the study and complete electronic patient-reported outcome (ePRO) questionnaires to help assess changes in health status over time. Study procedures include weekly home spirometry for all participants, with some participants also asked to complete daily pulse oximetry monitoring and/or weekly weight measurements, depending on study assignment. The study includes an initial in-person baseline visit and a final in-person visit at Month 12 at the UCSF Interstitial Lung Disease Clinic at the Parnassus Campus. Follow-up study visits at Months 3, 6, and 9 will be conducted remotely via Zoom. Participants will complete study-related assessments throughout the study period using electronic devices and questionnaires from home.

Keywords

Fibrotic Interstitial Lung Disease, IPF and PPF, Lung Fibrosis Interstitial, Interstitial lung disease, pulmonary fibrosis, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, Remote patient monitoring, Digital health, Telemonitoring, Home monitoring, Pragmatic study design, Real-world monitoring, Decentralized clinical trial, Interstitial Lung Diseases, Home Monitoring in Patients with f-ILD, Spirometer and Oximeter, Spirometer and Scale (weight), Spirometer, Oximeter, and Scale (weight)

Eligibility

You can join if…

Open to people ages 18 years and up

  • age 18 or older
  • English or Spanish speaking
  • have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Hypersensitivity Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for >10% of the ILD diagnoses seen at UCSF.

You CAN'T join if...

  • Patients who are unable provide informed consent for any reason or are acutely ill.

Location

  • University of California, San Francisco
    San Francisco California 94117 United States

Lead Scientist at University of California Health

  • Erica Farrand, MD (ucsf)
    Dr. Farrand is an Assistant Professor in the Division of Pulmonary, Critical Care, Sleep, Allergy and Sleep Medicine. She is attending physician in the Interstitial Lung Disease Program and on the Pulmonary Consult Service. Dr. Farrand's scholarship focuses on defining, assessing and improving the health care quality, safety and outcomes for individuals with interstitial lung disease.

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT07673237
Study Type
Interventional
Participants
Expecting 200 study participants
Last Updated